18F-FDG PET/CT在Erdheim-Chester病中的应用:影像表现与潜在BRAF突变生物标志物
回顾性分析2007—2017年32例病理确诊Erdheim-Chester病(ECD)患者的71次18F-FDG PET/CT,最常见受累部位为骨骼(90.6%)、肾脏(81.3%)和中枢神经系统(46.9%);BRAF V600E突变与CNS病变、更高SUVmax及更高死亡率相关,PET/CT结果影响48%(34/71)病例的临床管理。
要点
- ECD最常见受累部位为骨骼(90.6%)、肾脏(81.3%)和中枢神经系统(46.9%)。
- BRAF突变与18F-FDG高摄取CNS病变、更高SUVmax及更高死亡率相关。
- PET/CT结果影响48%(34/71)病例的临床管理。
核心结论
- 18F-FDG PET/CT结果可能作为BRAF突变存在的生物标志物,有助于建立诊断、指导活检并评估ECD患者的治疗反应。
- 轴性和骨盆骨骼受累比例高于既往报道。
研究设计与样本
- 回顾性审查本机构2007—2017年数据库,纳入病理证实的ECD患者32例,共行71次18F-FDG PET/CT检查。
- 两名放射科医师共识判读图像,影像表现与临床资料进行相关性分析。
主要发现
- 最活跃病灶的平均SUVmax为9.2(标准差6.1)。
- 最常见受累部位为骨骼(90.6%的患者,其中47%有轴性和骨盆骨骼受累)、肾脏(81.3%)和中枢神经系统(46.9%)。
- 26例患者检测了BRAF V600E突变,其中18例有突变、8例无突变。
- BRAF突变的存在与18F-FDG高摄取CNS病变(P=0.0357)、更高SUVmax(P=0.0044)及更高死亡率(P=0.0215)相关。
- CNS病变预测BRAF突变存在的特异性为88%,阳性预测值为92%。
关键数值与推荐
- BRAF突变与18F-FDG高摄取CNS病变相关(P=0.0357)。
- BRAF突变与更高SUVmax相关(P=0.0044)。
- BRAF突变与更高死亡率相关(P=0.0215)。
- CNS病变预测BRAF突变的特异性为88%,阳性预测值为92%。
- PET/CT检查结果影响48%的病例管理(34/71)。
临床怎么用
- 原文结论指出18F-FDG PET/CT结果可能作为BRAF突变存在的生物标志物,有助于建立诊断、指导活检并评估治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to evaluate 18F-FDG PET/CT for the diagnosis, management, and treatment of Erdheim-Chester disease (ECD). Methods: Our institutional database (2007-2017) was retrospectively reviewed for patients with pathologically proven ECD. A chart review yielded demographics, clinical information, and 5 categories of clinical impact. Two radiologists in consensus interpreted the images. Imaging findings were correlated with clinical data. Results: Seventy-one 18F-FDG PET/CT examinations were performed for 32 patients. The average SUVmax of the most active disease site was 9.2 (SD, 6.1). The most common sites involved were the skeleton (90.6% of patients, including 47% with axial and pelvic skeletal involvement), kidneys (81.3%), and central nervous system (CNS) (46.9%). Twenty-six patients were tested for a proto-oncogene B-Raf V600E (BRAF) mutation (18 had the mutation and 8 did not). The presence of a BRAF mutation was associated with 18F-FDG-avid CNS disease (P = 0.0357), higher SUVmax (P = 0.0044), and greater mortality (P = 0.0215). The presence of CNS disease had 88% specificity and a 92% positive predictive value for predicting the presence of a BRAF mutation. PET/CT examination results influenced patient management in 48% of cases (34/71). Conclusion:18F-FDG PET/CT results may act as a biomarker for the presence of a BRAF mutation, aid in establishing a diagnosis, guide biopsies, and gauge the treatment response in ECD patients. Axial and pelvic skeletal involvement is greater than previously reported.
引用
- Young JR, Johnson GB, Murphy RC, et al. 18F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. J Nucl Med. 2017. PMID: 29097410. doi:10.2967/jnumed.117.200741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。